|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fiedler GM, Baumann S, Leichtle A, Oltmann
A, Kase J, Thiery J and Ceglarek U: Standardized peptidome
profiling of human urine by magnetic bead separation and
matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry. Clin Chem. 53:421–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saito M, Kimoto M, Araki T, Shimada Y,
Fujii R, Oofusa K, Hide M, Usui T and Yoshizato K: Proteome
analysis of gelatin-bound urinary proteins from patients with
bladder cancers. Eur Urol. 48:865–871. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chou R, Gore JL, Buckley D, Fu R,
Gustafson K, Griffin JC, Grusing S and Selph S: Urinary biomarkers
for diagnosis of bladder cancer: A systematic review and
meta-analysis. Ann Intern Med. 163:922–931. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo A, Wang X, Gao L, Shi J, Sun C and Wan
Z: Bladder tumour antigen (BTA stat) test compared to the urine
cytology in the diagnosis of bladder cancer: A meta-analysis. Can
Urol Assoc J. 8:E347–E352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pichler R, Tulchiner G, Fritz J, Schaefer
G, Horninger W and Heidegger I: Urinary UBC rapid and NMP22 test
for bladder cancer surveillance in comparison to urinary cytology:
Results from a prospective single-center study. Int J Med Sci.
14:811–819. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Papale M, Vocino G, Lucarelli G,
Rutigliano M, Gigante M, Rocchetti MT, Pesce F, Sanguedolce F, Bufo
P, Battaglia M, et al: Urinary RKIP/p-RKIP is a potential
diagnostic and prognostic marker of clear cell renal cell
carcinoma. Oncotarget. 8:40412–40424. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Altieri DC: Survivin-The inconvenient IAP.
Semin Cell Dev Biol. 39:91–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
El-Hakim Abd TF, El-Shafie MK, Abdou AG,
Azmy RM, El-Naidany SS and El-Din Badr MO: Value of urinary
survivin as a diagnostic marker in bladder cancer. Anal Quant
Cytopathol Histpathol. 36:121–127. 2014.PubMed/NCBI
|
|
11
|
Meng Y, Wang L, Chen D, Chang Y, Zhang M,
Xu JJ, Zhou R and Zhang QY: LAPTM4B: An oncogene in various solid
tumors and its functions. Oncogene. 35:6359–6365. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang Y, Xu J and Zhang Q: Microplate
magnetic chemiluminescence immunoassay for detecting urinary
survivin in bladder cancer. Oncol Lett. 14:4043–4052. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Zhang QY and Wang YM: Cloning of
survivin gene and preparation its monoclonal antibodies as well as
checking survivin expression in liver carcinoma cells. Chin J Lab
Med. 29:258–262. 2006.(In Chinese).
|
|
14
|
Chatziharalambous D, Lygirou V, Latosinska
A, Stravodimos K, Vlahou A, Jankowski V and Zoidakis J: Analytical
performance of ELISA assays in urine: One more bottleneck towards
biomarker validation and clinical implementation. PLoS One.
11:e01494712016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thway T and Salimi-Moosavi H: Evaluating
the impact of matrix effects on biomarker assay sensitivity.
Bioanalysis. 6:1081–1091. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X, Lin JM and Ying X: Evaluation of
carbohydrate antigen 50 in human serum using magnetic
particle-based chemiluminescence enzyme immunoassay. Anal Chim
Acta. 598:261–267. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Q, Wang X, Li Z and Lin JM:
Evaluation of alpha-fetoprotein (AFP) in human serum by
chemiluminescence enzyme immunoassay with magnetic particles and
coated tubes as solid phases. Anal Chim Acta. 631:212–217. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X, Zhang QY, Li ZJ, Ying XT and Lin
JM: Development of high-performance magnetic chemiluminescence
enzyme immunoassay for alpha-fetoprotein (AFP) in human serum. Clin
Chim Acta. 393:90–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Horstmann M, Bontrup H, Hennenlotter J,
Taeger D, Weber A, Pesch B, Feil G, Patschan O, Johnen G, Stenzl A
and Brüning T: Clinical experience with survivin as a biomarker for
urothelial bladder cancer. World J Urol. 28:399–404. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen HA, Su CM, Hsieh HY, Tung CL, Hsu CD,
Wang YH and Shen CH: Clinical significance of survivin expression
in patients with urothelial carcinoma. Dis Markers.
2014:5749852014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gogalic S, Sauer U, Doppler S and
Preininger C: Bladder cancer biomarker array to detect aberrant
levels of proteins in urine. Analyst. 140:724–735. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schmidt J, Propping C, Siow WY,
Lohse-Fischer A, Toma M, Baldauf-Twelker A, Hakenberg OW, Wirth MP
and Fuessel S: Diagnostic and prognostic value of bladder
cancer-related transcript markers in urine. J Cancer Res Clin
Oncol. 142:401–414. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sah NK and Seniya C: Survivin splice
variants and their diagnostic significance. Tumour Biol.
36:6623–6631. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zamparese R, Pannone G, Santoro A, Lo
Muzio L, Corsi F, Pedicillo MC, Scillitani EL, Tortorella S,
Staibano S, Piscuoglio S, et al: Survivin expression in renal cell
carcinoma. Cancer Invest. 26:929–935. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Byun SS, Yeo WG, Lee SE and Lee E:
Expression of survivin in renal cell carcinomas: Association with
pathologic features and clinical outcome. Urology. 69:34–37. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lei Y, Geng Z, Guo-Jun W, He W and
Jian-Lin Y: Prognostic significance of survivin expression in renal
cell cancer and its correlation with radioresistance. Mol Cell
Biochem. 344:23–31. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi ZG, Li SQ, Li ZJ, Zhu XJ, Xu P and Liu
G: Expression of vimentin and survivin in clear cell renal cell
carcinoma and correlation with p53. Clin Transl Oncol. 17:65–73.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Adachi J, Kumar C, Zhang Y, Olsen JV and
Mann M: The human urinary proteome contains more than 1500
proteins, including a large proportion of membrane proteins. Genome
Biol. 7:R802006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baytekin F, Tuna B, Mungan U, Aslan G and
Yorukoglu K: Significance of P-glycoprotein, p53, and survivin
expression in renal cell carcinoma. Urol Oncol. 29:502–507. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang Y, Yang H, McNutt MA, Xiong F, Nie X,
Li L and Zhou R: LAPTM4B overexpression is an independent
prognostic marker in ovarian carcinoma. Oncol Rep. 20:1077–1083.
2008.PubMed/NCBI
|
|
31
|
Zhou L, He XD, Cui QC, Zhou WX, Qu Q, Zhou
RL, Rui JA and Yu JC: Expression of LAPTM4B-35: A novel marker of
progression, invasiveness and poor prognosis of extrahepatic
cholangiocarcinoma. Cancer Lett. 264:209–217. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kang Y, Yin M, Jiang W, Zhang H, Xia B,
Xue Y and Huang Y: Overexpression of LAPTM4B-35 is associated with
poor prognosis in colorectal carcinoma. Am J Surg. 204:677–683.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang H, Xiong FX, Lin M, Yang Y, Nie X and
Zhou RL: LAPTM4B-35 overexpression is a risk factor for tumor
recurrence and poor prognosis in hepatocellular carcinoma. J Cancer
Res Clin Oncol. 136:275–281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li S, Wang L, Meng Y, Chang Y, Xu J and
Zhang Q: Increased levels of LAPTM4B, VEGF and survivin are
correlated with tumor progression and poor prognosis in breast
cancer patients. Oncotarget. 8:41282–41293. 2017.PubMed/NCBI
|
|
35
|
Zerefos PG and Vlahou A: Urine sample
preparation and protein profiling by two-dimensional
electrophoresis and matrix-assisted laser desorption ionization
time of flight mass spectroscopy. Methods Mol Biol. 428:141–157.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li L, Shan Y, Yang H, Zhang S, Lin M, Zhu
P, Chen XY, Yi J, McNutt MA, Shao GZ and Zhou RL: Upregulation of
LAPTM4B-35 promotes malignant transformation and tumorigenesis in
L02 human liver cell line. Anat Rec (Hoboken). 294:1135–1142. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sjödahl G, Lövgren K, Lauss M, Patschan O,
Gudjonsson S, Chebil G, Aine M, Eriksson P, Månsson W, Lindgren D,
et al: Toward a molecular pathologic classification of urothelial
carcinoma. Am J Pathol. 183:681–691. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Eriksson P, Aine M, Veerla S, Liedberg F,
Sjödahl G and Höglund M: Molecular subtypes of urothelial carcinoma
are defined by specific gene regulatory systems. BMC Med Genomics.
8:252015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li Z, Li X, Li C, Su Y, Fang W, Zhong C,
Ji W, Zhang Q and Su C: Transcription factor OCT4 promotes cell
cycle progression by regulating CCND1 expression in esophageal
carcinoma. Cancer Lett. 354:77–86. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cao L, Li C, Shen S, Yan Y, Ji W, Wang J,
Qian H, Jiang X, Li Z, Wu M, et al: OCT4 increases BIRC5 and CCND1
expression and promotes cancer progression in hepatocellular
carcinoma. BMC Cancer. 13:822013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Elmegeed GA, Yahya SM, Abd-Elhalim MM,
Mohamed MS, Mohareb RM and Elsayed GH: Evaluation of heterocyclic
steroids and curcumin derivatives as anti-breast cancer agents:
Studying the effect on apoptosis in MCF-7 breast cancer cells.
Steroids. 115:80–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Diaz A, Valera A, Carrera C, Hakim S,
Aguilera P, García A, Palou J, Puig S, Malvehy J and Alos L:
Pigmented spindle cell nevus: Clues for differentiating it from
spindle cell malignant melanoma. A comprehensive survey including
clinicopathologic, immunohistochemical, and FISH studies. Am J Surg
Pathol. 35:1733–1742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sun L, Hu H, Peng L, Zhou Z, Zhao X, Pan
J, Sun L, Yang Z and Ran Y: P-cadherin promotes liver metastasis
and is associated with poor prognosis in colon cancer. Am J Pathol.
179:380–390. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Breyer J, Gierth M, Shalekenov S, Aziz A,
Schäfer J, Burger M, Denzinger S, Hofstädter F, Giedl C and Otto W:
Epithelial-mesenchymal transformation markers E-cadherin and
survivin predict progression of stage pTa urothelial bladder
carcinoma. World J Urol. 34:709–716. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rodriguez L, Villalobos X, Dakhel S,
Padilla L, Hervas R, Hernández JL, Ciudad CJ and Noé V: Polypurine
reverse Hoogsteen hairpins as a gene therapy tool against survivin
in human prostate cancer PC3 cells in vitro and in vivo. Biochem
Pharmacol. 86:1541–1554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jiang Y, Saavedra HI, Holloway MP, Leone G
and Altura RA: Aberrant regulation of survivin by the RB/E2F family
of proteins. J Biol Chem. 279:40511–40520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mirza A, McGuirk M, Hockenberry TN, Wu Q,
Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, et al:
Human survivin is negatively regulated by wild-type p53 and
participates in p53-dependent apoptotic pathway. Oncogene.
21:2613–2622. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang Q and Greene MI: EGFR enhances
Survivin expression through the phosphoinositide 3 (PI-3) kinase
signaling pathway. Exp Mol Pathol. 79:100–107. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tian M, Chen Y, Tian D, Qiao X, Ma Z and
Li J: Beclin1 antagonizes LAPTM4B-mediated EGFR overactivation in
gastric cancer cells. Gene. 626:48–53. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tan X, Sun Y, Thapa N, Liao Y, Hedman AC
and Anderson RA: LAPTM4B is a PtdIns(4,5)P2 effector that regulates
EGFR signaling, lysosomal sorting, and degradation. EMBO J.
34:475–490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Momeny M, Zarrinrad G, Moghaddaskho F,
Poursheikhani A, Sankanian G, Zaghal A, Mirshahvaladi S, Esmaeili
F, Eyvani H, Barghi F, et al: Dacomitinib, a pan-inhibitor of ErbB
receptors, suppresses growth and invasive capacity of
chemoresistant ovarian carcinoma cells. Sci Rep. 7:42042017.
View Article : Google Scholar : PubMed/NCBI
|
